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Abstract The concomitant presence of a pituitary ade-
noma with a second sellar lesion in patients operated upon
for pituitary adenoma is an uncommon entity. Although
rare, quite a great variety of lesions have been indentiﬁed
coexisting with pituitary adenomas. In fact, most combi-
nations have been described before, but an overview with
information on the frequency of combined pathologies in a
large series has not been published. We present a series of
eight collision sellar lesions indentiﬁed among 548 trans-
sphenoidally resected pituitary adenomas in two Neuro-
surgical Departments. The histological studies conﬁrmed a
case of sarcoidosis within a non-functioning pituitary
adenoma, a case of intrasellar schwannoma coexisting with
growth hormone (GH) secreting adenoma, two Rathke’s
cleft cysts combined with pituitary adenomas, three gan-
gliocytomas associated with GH-secreting adenomas, and a
case of a double pituitary adenoma. The pertinent literature
is discussed with emphasis on pathogenetic theories of dual
sellar lesions. Although there is no direct evidence to
conﬁrm the pathogenetic relationship of collision sellar
lesions, the number of cases presented in literature makes
the theory of an incidental occurrence rather doubtful.
Suggested hypotheses about a common embryonic origin
or a potential interaction between pituitary adenomas and
the immune system are presented.
Keywords Adenoma  Collision tumors 
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Introduction
Collision tumors represent two morphologically different
tumors attached to each other. Extending this deﬁnition,
collision lesions refer to histologically different patholog-
ical conditions found in combination and may include
neoplastic, vascular, congenital, or infectious/inﬂammatory
lesions. The presence of a collision sellar lesion represents
a very uncommon event. A preoperative diagnosis of a dual
sellar pathology is very difﬁcult, since most of the cases are
presented clinically and radiologically as pituitary adeno-
mas. The deﬁnitive diagnosis of a collision sellar lesion is
determined by the histological study. Even after histolog-
ical conﬁrmation, some ‘‘combined pathologies’’ could be
debatable given their essentially similar pathogenesis.
However, a determined pathogenetic mechanism to explain
the coexistence of different lesions in the sella has not been
proven. The aim of this study is to report the experience of
collision sellar lesions in surgical series and to emphasize
on the theories of their origin and pathogenesis with review
of the literature.
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We retrospectively studied the histological examinations
and medical ﬁles of eight patients with dual sellar lesions
among 548 individuals who underwent transsphenoidal
surgery (TSS) for pituitary adenomas during the last
5 years in two Neurosurgical Departments.
The pathological examination included histological,
histochemical and immunocytological studies. For light
microscopy, 4–6 lm sections of formalin-ﬁxed and paraf-
ﬁn-embedded tissue were stained by the hematoxylin and
eosin and the periodic acid-Shiff (PAS) methods. Perox-
idase-antiperoxidase and avidin-biotin-peroxidase complex
(ABC) techniques were utilized to demonstrate the presence
of anedohypophysial hormones. Antisera were directed
against the following pituitary hormones: growth hormone
(GH; dilution 1:4000), prolactin (PRL; dilution 1:3000),
adrenocorticotropic hormone (ACTH; (dilution 1:2500),
b-thyroid stimulating hormone (b-TSH; dilution 1:2000),
b-follicle stimulating hormone (b-FSH; dilution 1:1500),
b-luteinizing hormone (b-LH; dilution 1:2000) and a-sub-
unit of glycoprotein hormones (a-SU; dilution 1:1500).
In addition, keratin 8 (CAM 5.2, dilution 1:50, Becton-
Dickinson, San Jose, CA, USA) was used to demonstrate
the ﬁbrous bodies. Before application of the primary
antibody, sections were treated with 1 mg/100 ml pronase
E (Sigma Chemical Companies, St. Louis, MO, USA) at
room temperature. Incubations with primary antibodies
were carried out overnight at 4C. All antisera used to
localize pituitary hormones were donated from the National
Hormone and Pituitary Program (NHPP) Torrance,
California, USA. Additional immunostains were per-
formed using the following antisera: S-100 protein, glial
ﬁbrillary acidic protein, neuron-speciﬁc enolase, chro-
mogranin A, synaptophysin, neuroﬁlament protein (NFP),
GH-releasing hormone. The proliferation index of the
adenomas was estimated using the Ki-67 antibody (clone
MIB-1).
Medical ﬁles were retrospectively reviewed. All patients
were preoperatively evaluated by endocrinologists. Endo-
crine examination included fasting blood cortisol, ACTH,
PRL, GH, insulin-like growth factor 1 (IgF1), LH, FSH,
testosterone/estradiol, TSH, thyroxine (T4) and trijodo-
thyronine (T3) serum levels.
Preoperative magnetic resonance imaging (MRI) studies
of the patients were also retrospectively analyzed. Avail-
able MRI studies of the sellar region were performed with
3 mm scans in sagittal and coronal planes and included
T1-weighted sequences, T1-weighted images after admin-
istration of gadolinium (Gd) and T2-weighted images.
Maximum tumor diameter and location of sellar lesion as
well as the post-contrast enhancement pattern were
assessed.
Results
During the last 5 years, 548 patients with pituitary ade-
nomas were operated via TSS in two Neurosurgical
Departments. In eight cases (1.46%), a dual sellar pathol-
ogy was histologically diagnosed, composed of mixed tis-
sue elements of adenohypophysial adenoma and a second
sellar lesion, of either adenomatous or nonadenomatous
origin. The cohort included ﬁve females and three males
with median age of 48 years (range 38–76 years). Based on
clinical and radiological ﬁndings, all patients underwent
TSS with a preoperative diagnosis of pituitary adenoma.
The histological studies deﬁning the concomitance of a
pituitary adenoma with a second sellar lesion are summa-
rised in Table 1. The histological diagnosis conﬁrmed a
case of sarcoidosis within a non-functioning pituitary ade-
noma (NFPA) (Fig. 1), three cases of gangliocytoma asso-
ciated with GH-secreting pituitary adenoma (Figs. 2, 3), a
schwannoma coexisting with GH-secreting adenoma, a case
of double adenoma consisting of a GH-secreting adenoma
and a prolactinoma (Fig. 4), and two Rathke’s cleft cysts
(RCC) with a concomitant pituitary adenoma, speciﬁcally
an ACTH-secreting and a NFPA adenoma (Fig. 5). The
case of intrasellar schwannoma coexisting with a GH-
secreting adenoma has already been accepted for publica-
tion. In case of neurosarcoidosis within an adenoma, the
ﬁnal diagnosis was deﬁnite when systemic pulmonary dis-
ease was determined, 3 years after the initial operation.
Table 2 provides a summary of clinical presentation,
preoperative treatment, MRI ﬁndings, histological diagno-
ses, surgical results and adjuvant management of the eight
collision sellar cases, in a mean follow up period of
37.9 months (range 18–55 months).
In every case only the pituitary adenoma was symp-
tomatic. Six patients presented with hypersecretory symp-
toms and were all histologically diagnosed with a
hormone-active adenoma; three of them were preopera-
tively treated with somatostatin analogs or dopamine
agonists. Four patients presented with varying degree of
pituitary insufﬁciency requiring hormonal replacement
therapy in two of them. No symptoms characteristic of the
coexisting lesion were observed in any of the cases.
On the preoperative MRI, the tumor diameter ranged
between 11 and 25 mm. In two cases, a parasellar exten-
sion of the tumor was observed. All lesions enhanced either
homogenously or heterogeneously after Gd administration.
None the MRI ﬁndings, summarized in Table 2, pro-
claimed the presence of a collision sellar lesion, so that in
every case the preoperative diagnosis was a pituitary ade-
noma (Figs. 6, 7).
One patient (No. 2) underwent a second TSS 3 years
after the initial operation due to the recurrence of the
lesion; the histological diagnosis of the second operation
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123conﬁrmed the same dual pathology of sarcoidosis within a
pituitary adenoma. Further treatment for the rest of the
cases was decided according to the surgical outcome and
the histological study.
Discussion
The occurrence of collision sellar lesions is very uncom-
mon accounting for 1.46% in the present series. Given the
clinical and imaging similarities to pituitary adenomas, the
diagnosis of a dual pathological condition of the sella is
Fig. 1 Patient No. 2. Pituitary null cell adenoma combined with
granulomatous inﬂammation due to neurosarcoidosis. The pituitary
adenoma consists of highly vascularized tissue (asterisks in some
vessel lumina) and a monomorphous population of epitheloid tumor
cells with eosinophilic cytoplasm; in the upper right hand corner a
non-necrotizing granuloma is present consisting of histiocytes, some
multinucleate giant cells (example indicated by arrow) and collec-
tions of small lymphocytes (arrowheads). Hematoxylin & Eosin
staining 9100
Fig. 2 Patient No. 5. Gangliocytoma coexisting with sparsely
granulated somatotroph adenoma. The adenoma part consists of
small chromophobic cells with typical cytoplasmic ﬁbrous bodies
(arrows). The gangliocytic component comprises large, polyhedral,
mature ganglion cells with abundant cytoplasm and spheroid nuclei.
Hematoxylin & Eosin staining 920
Table 1 Histological studies deﬁning the concomitant of a pituitary adenoma with a second sellar lesion
No. Pituitary adenoma 2nd sellar lesion Conclusion
1 Basophilic ACTH immunoreactive PAS-positive mucin, cystic wall with
columnar epithelium
ACTH-secreting pituitary adenoma
coexisting with RCC
2 Chromophobic immunonegative (null cell)
adenoma
Granoulomas formation without necrosis
possibly secondary to sarcoidosis
Neurosarcoidosis within a null cell
pituitary adenoma
a
3 Chromophobic sparsely granulated GH
immunoreactive, locally immunopositive
for PRL, immunoreactive for NFP
Ganglion cells within a ﬁbrillary substrate Gangliocytoma combined with a GH-
secreting pituitary adenoma
4 Chromophobic sparsely granulated GH
immunoreactive
Well-circumscribed schwannoma Antoni
A type with parallel-organised spindle-
shaped cells around hypocellular areas
(‘‘Verocay bodies’’)
GH-secreting pituitary adenoma
coexisting with an intrasellar
schwannoma
5 Chromophobic sparsely granulated GH
immunoreactive, locally immunopositive for
PRL and a-SU, immunoreactive for NFP
Large ganglion cells embedded in a dense
neuropil substrate
Gangliocytoma combined with a GH-
secreting pituitary adenoma
6 Chromophobic, GH immunoreactive, locally
immunopositive for a-SU
Chromophobic PRL immunoreactive
pituitary adenoma
Double adenoma consisting of a GH- and
a PRL-secreting pituitary adenoma
7 Chromophobic, immunoreactive mainly
for b-LH and locally for b-FSH
Cystic formation of Rathke’s cleft with a
diameter of 0.1 cm, PAS-negative
Gonadotroph pituitary adenoma
coexisting with RCC
8 Chromophobic sparsely granulated GH
immunoreactive, locally immunopositive
for PRL, immunoreactive for NFP
Ganglion cells embedded in a ﬁbrillary
substrate
Gangliocytoma combined with
a GH-secreting pituitary adenoma
a-SU a-subunit of glycoprotein hormones, b-FSH b-follicle stimulating hormone, b-LH b-luteinizing hormone, ACTH adrenocorticotropic
hormone, GH growth hormone, NFP neuroﬁlament protein, PAS periodic acid-Shiff, PRL prolactin, RCC Rathke’s cleft cyst
a The ﬁnal diagnosis of neurosarcoidosis was determined 3 years after surgery when the pulmonary disease was veriﬁed
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123usually based on the histological study. To date, very few
surgical series have been reported describing speciﬁc
combinations of sellar lesions like a double pituitary ade-
noma [1, 2], a combination of an adenoma with RCC [3–5]
or a gangliocytoma associated with a pituitary adenoma
[6–8]. Mainly, case reports have been published, demon-
strating the concomitance of two different pathologies
within the sella. Most publications include a pituitary
adenoma coexisting with a second lesion like a cranio-
pharyngioma [9], arachnoid cyst [10], colloid cyst [11],
epidermoid cyst [12], lymphocytic hypophysitis [13, 14],
granulomatous hypophysitis [15], sarcoidosis within a
pituitary adenoma [16] and metastatic carcinoma to pitui-
tary adenoma [17–19]. Although it could be claimed that
these entities would be expected as incidental occurrences,
the great variety of coexisting lesions with a pituitary
adenoma make this hypothesis rather doubtful. Many
theories have suggested explanations for potential patho-
genetic relationship between the concomitant lesions. Still,
clear evidence of this relation has not been proven.
A review for each collision sellar lesion encountered in
our series is herein discussed with emphasis on possible
pathogenetic origins.
Pituitary adenoma and concomitant Rathke’s Cleft Cyst
The incidental ﬁnding of small, asymptomatic RCC in
autopsy specimens of normal pituitary glands climbs up to
33% [20]. However, the coexistence of RCC with a pitui-
tary adenoma is rare. In a large clinicopathologic study of
464 cases [3], the rate of coincidence was 1.7%, and in a
recent report [4] only 4 concomitant RCC were identiﬁed
among 782 cases with known pituitary adenoma (0.51%).
Although Sumida et al. [5] reported a coincidence rate of
Fig. 4 Patient No. 6. Left: Tissue fragment of chromophobic
adenoma with focal immunoreactivity for GH, typical for the sparsely
granulated variant of somatotroph adenomas. Avidin-biotin-peroxi-
dase complex method 920. Right: Another fragment from the same
specimen immunopositive for PRL, with the characteristic paranu-
clear, dot-like localization of chromogen. Avidin-biotin-peroxidase
complex method 920
Fig. 3 Patient No. 8. Ganglion cells admixed with acidophil cells of a
densely granulated somatotroph adenoma. Note the presence of
prominent nucleoli in ganglion cell and the ﬁbrillary neuropil in the
stroma. Hematoxylin & Eosin staining 920
Fig. 5 Patient No. 7. Rathke’s cleft cyst with single cell lining
immunoreactive for keratin 8. The lumen contains colloidal material.
The surrounded tissue corresponds to chromophobic pituitary ade-
noma. Avidin-biotin-peroxidase complex method 910
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1233.5% in 228 patients with pituitary adenomas, their study
was based on radiological ﬁndings and only two among
eight presumed RCC were histologically conﬁrmed, mak-
ing this high percentage rather questionable. In our data-
base, two cases of collision RCC and pituitary adenoma
were histologically diagnosed (No. 1 and 7) giving a per-
centage of 0.74% among the patients operated for pituitary
adenomas.
On a recent review of the literature, Noh et al. [4]
identiﬁed only 32 reported cases of a pituitary adenoma
and a concomitant RCC. According to this review, most
adenomas were prolactinomas. In total, the reported cases
included 13 prolactinomas, 9 GH-, 2 ACTH-secreting
adenomas, 3 mixed adenomas and 5 NFPA. In all these
cases only the pituitary adenomas were symptomatic,
which was true in our two patients as well. However, only
in 26 among 32 cases the diagnosis of a coexisted RCC was
conﬁrmed histologically [4].
A preoperative diagnosis of these collision sellar lesions
based on MRI ﬁndings is very difﬁcult [4, 5]. When
radiologically discriminated, RCC show variable position,
size, and signal intensity on MRI, and there is no speciﬁc
pattern of pituitary displacement [4, 5]. The MRI intensity
of RCC depends on protein concentration [21, 22]. Only in
15 of 32 reported cases of collision RCC and pituitary
adenoma [4] the lesion contained two different signal
intensities on MRI. In none of our cases the lesions were
radiologically distinguishable from each other.
The pathogenesis of these rare collision lesions is still
unclear. Initially, in 1978, Kepes [23] described a transi-
tional cell tumor of the pituitary gland developing from a
RCC, considering that the tumor was derived from ‘‘tran-
sitional’’ cells between the lining cells of Rathke’s cleft
and the glandular cells of the anterior pituitary. This theory
was rejected by Ikeda et al. [24] who proved that the tumor
described by Kepes [23] corresponded to an early devel-
opmental stage of the pituitary anterior lobe and that a cyst
within a pituitary adenoma differs from cysts found in the
embryonic stage of the pituitary gland. Another theory
concerning the pathogenesis of the concurrence of prolac-
tinoma and RCC [25] suggested a prolactin cell stimulation
from an existing RCC which results in a secondary ade-
noma formation. We disagree with this theory as it is
against the monoclonal origin of pituitary adenomas
[26, 27]. Furthermore, such a theory cannot be applied
when the pituitary adenoma coexisting with a RCC is other
than a prolactinoma, as happened in our two cases.
In conclusion, the pathogenesis of compound pituitary
adenomas and RCC remains to be clariﬁed. Rathke’s pouch
gives rise to the anterior pituitary lobe via proliferation of
its anterior wall, and the anterior pituitary lobe is known to
give rise to pituitary adenomas through clonal alteration
[3, 26, 27]. Therefore, RCC deriving from remnants of
Rathke’s pouch [28, 29] and pituitary adenomas could be
suggested to have a common embryonic origin. However,
this histogenetic link between RCC and pituitary adenomas
has not been proven yet.
Multiple pituitary adenomas
Multiple adenomas are deﬁned as morphologically or
immunohistologically distinct adenomas found in the same
specimen [1] and have to be distinguished from mixed
adenomas, where mixed cell populations demonstrates
immunoreactivity for two or more hormones [1, 30]. The
incidence of multiple pituitary adenomas in autopsies is not
Fig. 7 Patient No. 8. Preoperative coronal T1-weighted MRI dem-
onstrating a sellar lesion attached to the left cavernous sinus,
stretching the pituitary gland to the right and slightly deviating the
pituitary stalk. Given the clinical presentation, the lesion was
considered to be a GH-secreting pituitary adenoma
Fig. 6 Patient No. 2. Preoperative coronal T1-weighted MRI show-
ing a sellar lesion of 20 mm with suprasellar extension suggesting a
preoperative diagnosis of a non-functioning pituitary adenoma
12 Pituitary (2010) 13:8–17
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123so rare and the diagnostic criteria include tumors that
exhibit different immunoreactivities or tumors with the
same immunoproﬁle, which are located in different ana-
tomical sites and show dissimilar histological patterns [31].
Kontogeorgos et al. [31], in the largest ever reported
autopsy study of more than 9,300 pituitary glands, identi-
ﬁed 20 cases of multiple adenomas accounting of 0.9% of
incidentally pituitary adenoma cases. Other authors have
reported higher rates of multiple adenomas in autopsy, like
7[ 32], 10% [33], or even more than 10.5% [34].
In surgical series, the incidence of multiple adenomas is
lower compared with autopsy series and this is mainly due
to fragments of surgical specimens [1]. Their initial diag-
nosis must be based upon light microscopic criteria, such as
demonstration of distinct pattern variation and differences
in cytological features and hormone content. Thus, ade-
noma fragments showing dissimilar histological and
ultrastructural features can be considered to represent two
distinct adenomas. Alternatively, histologically similar
tissue fragments may correspond to separate adenomas if
they exhibit different hormone immunoreactivities and
ultrastructural features [1]. In a large surgical cohort of
more than 3,000 resected pituitary adenomas the percent-
age of double adenomas was 0.37% [1]. In our experience
the rate was 0.18%. This low incidence in the present
limited number of cases may reﬂect the signiﬁcant diag-
nostic problem when the surgical specimen contains only
minute fragments of the second adenoma. Actually, a sig-
niﬁcant number of supernumerary pituitary adenomas is
likely to remain undiagnosed in surgical series [1]. How-
ever, rates as high as 1.3% have been published [2]. The
commonest hormone-active adenoma identiﬁed in surgical
series of double adenomas is GH-secreting adenoma [1, 2],
as in our report.
Given the frequency of pituitary incidentalomas, a
coincidental occurrence of a second adenoma could be
expected. However, some theories trying to provide a
causal link between multiple pituitary adenomas have been
suggested. One is the occurrence of different clonal pro-
liferation within originally one adenoma resulting in partial
transformation of the adenoma to another phenotype [1, 2].
Although it has been shown that most pituitary adenomas
are monoclonal in origin, the possibility exists that new
clones may develop during the progression of an adenoma
[35, 36]. Thus, it may be that adenoma proﬁles are unstable
and subject to change under modiﬁed microenvironmental
conditions [1]. Another theory suggests that one adenoma
can induce the formation of another adenoma. This
hypothesis can be better applied in cases of GH-secreting
adenomas which release substances like GH and IgF1 that
may promote the secondary adenoma growth [1, 2]. Fur-
thermore, in a recent study [27], several pituitary-driven
growth factors had been shown to induce pituitary
hyperplasia with or without ultimate adenoma development
when expressed in transgenic mice. Last, the role of altered
hypothalamic function due to a primary pituitary tumor can
be considered in the development of a new adenoma.
Occasionally, multifocal polyclonal pituitary adenomas
associated with hyperprolactinemia may arise either due to
extrinsic changes in hypothalamic factors, or to pituitary
stalk compression, blocking lactotroph inhibition by
dopamine [27].
None of the proposed pathogenetic mechanisms have
been proven. Resent promising studies [27] mainly based
on molecular analysis provide new insights in under-
standing the multidirectional mechanisms underlying the
pituitary adenomatogenesis. Main factors considered in
pituitary tumorigenesis include both intrinsic pituicyte
alterations and altered availability of regulatory factors
including hypothalamic hormones, peripheral hormones,
and paracrine growth factors.
Gangliocytoma associated with pituitary adenoma
Gangliocytomas are rare entities of undetermined histo-
genesis [7, 8, 37, 38]. Gangliocytomas associated with
pituitary adenomas are mixed tumors composed of both
adenomatous and gangliocytic elements; ganglion cells are
described within a variably dense ﬁbrillary substrate and
are frequently associated with adenomatous proliferation of
pituitary cells [8]. To date, approximately 65 cases have
been reported [8]. In a series of 1,322 sellar lesions, gan-
gliocytomas associated with pituitary adenomas were
estimated to account 0.52% of sellar tumors [8]. Other
authors report an incidence of 1.26% [39]. In our experi-
ence, the percentage was 0.55%.
Most patients are females and up to three-quarters of
them are preoperatively diagnosed as having GH-secreting
pituitary adenoma [7, 8, 38, 39], as was true for all three
cases in our series (No. 3, 5 and 8). In a few reported cases
the tumor presented with symptoms of Cushing’s disease or
of excessive PRL secretion [7, 38, 40, 41]. In GH-pro-
ducing tumors, the neuronal component is almost exclu-
sively associated with a sparsely granulated somatotroph
adenoma [7, 8, 38], a feature found in all three cases in this
series. Neither imaging nor intraoperative ﬁndings reveal
any differences between gangliocytoma and pituitary ade-
noma, so that the initial diagnosis is that of a GH-secreting
pituitary adenoma [8].
The origin of gangliocytomas is still unclear. The theory
of an incidental ﬁnding was supported by the hypothesis of
abnormal migration of hypothalamic neurons within the
adenohypophysial parenchyma during the early phase of
embryogenesis [42]. Thus, these mixed tumors may rep-
resent an incidental concurrence of a pituitary adenoma in
a pre-existing neuronal choristoma. Another theory
14 Pituitary (2010) 13:8–17
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hormones locally produced by the ganglion cells promote
the adenoma formation by adenohypophysial cells stimu-
lation. This hypothesis is strengthened by the presence of
hypophysiotropic hormones within the neurons of gan-
gliocytomas corresponding to the relevant pituitary hor-
mones secreted by adenoma cells [6, 43]. However, lack of
correlation between adenoma cell type and the corre-
sponding releasing hypothalamic hormone within ganglion
cells in some tumors weakens this hypothesis [8]. A third
hypothesis suggests the origin of the neuronal component
from neuronal differentiation of a pre-existing pituitary
adenoma reporting the presence of transitional cell forms
between neurons and adenohypophysial cells [44]. Vidal
et al. [45] supports the assumption of neuronal metaplasia
of pituitary adenoma cells describing that somatotrophs
exhibit plasticity and under certain conditions they can
undergo transdifferentiation. Moreover, the documented
presence of nerve growth factor (NGF) in various adenoma
cell types [46] and the evidence that NGF receptors are
present in adenoma cells [47] further supports this theory.
Although this assumption may be challenging, we remain
critical, as it is difﬁcult to completely understand the
transformation of a neoplastic pituitary cell to a well-dif-
ferentiated mature neuron with the dominating embryo-
logical concepts [8].
Recently, a common origin of both adenomatous and
neuronal component of the pituitary gangliocytomas has
been suggested [8]. The adult pituitary gland has been
proven to contain a cell population displaying character-
istics of stem/progenitor cell [48]. Kontogeorgos et al. [8]
reappraised this theory, based on the common origin of
both neuronal and adenohypophysial components from
uncommitted stem/progenitor cells capable of multidirec-
tional differentiation. In this study, the authors concluded
that the presence of NFP in the adenoma cell compartment
of gangliocytomas indicates neuronal differentiation in
adenoma cells, suggesting a common origin for neuronal
and pituitary adenoma cell elements in gangliocytomas. In
all our three specimens, the adenoma compartment was
examined and found immunoreactive for NFP, further
supporting the later theory.
Pituitary adenoma concomitant with intrasellar
schwannoma
Intrasellar schwannomas are extremely rare and to date
less than 15 cases have been reported [49–61]. In none of
these cases, a preoperative diagnosis was possible based
on MRI evaluation or clinical presentation. The origin of
intrasellar schwannomas remains unclear, however, some
theories concerning their histogenesis have been proposed.
Extension in the sella from a cranial nerve within the
cavernous sinus could be possible [53, 59], although, in
this case, cranial nerve symptoms must be expected. A
very interesting theory has been suggested by Bleys et al.
[62] considering a possible origin of intrasellar schwan-
nomas from the lateral sellar nerve plexus. Other
hypotheses about intrasellar schwannomas’ origin include
perivascular nerve plexus, multipotential mesenchymal
cells, displaced neural crest cells and ectopic Schwann
cells [56, 63].
Our case of coexistent GH-secreting pituitary adenoma
with an intrasellar schwannoma (No. 4) is recently
published [64] and represents the only documented report
of such an uncommon entity. The literature provides
no data explaining a possible interaction between GH-
secreting pituitary adenomas and intrasellar schwanno-
mas, or a possible common origin of the two tumors.
Thus, their coexistence should be considered incidental
ﬁnding.
Sarcoidosis within a pituitary adenoma
Neurosarcoidosis is present in 5–15% of patients with
systemic disease mainly affecting the hypothalamic-pitui-
tary region through lymphocytic and granulomatous inﬁl-
trates of the basilar meninges or as part of local or diffuse
disease of the CNS parenchyma [65]. However, the pres-
ence of neurosarcoidosis within a pituitary adenoma has
only been reported once in literature [16]. In the case of
Rubin et al. [16], the patient had already lung disease at the
time of presentation. In our patient (No. 2), pulmonary
disease was manifested 3 years after the initial TSS and
remained clinically silent, no indicating treatment. In none
case, the preoperative MRI ﬁndings were distinguishable
from a pituitary adenoma. In both patients, pituitary
insufﬁciency remained after treatment, requiring replace-
ment therapy. Interestingly, recurrence in our patient
occurred in both tumors population.
Although there is no proven mechanism to explain the
coexistence of sarcoid and pituitary adenoma, interesting
theories concerning the pathogenesis of pituitary inﬂam-
mation [66] and the potential interaction between pituitary
adenomas and the immune system have been proposed
[14]. In their article, Moskowitz et al. [14] discuss the
concurrence of lymphocytic hypophysitis and other intra-
sellar lesions, such as pituitary adenomas. The authors
support the theory that normal and neoplastic pituitary can
stimulate an inﬂammatory reaction via expression of mul-
tiple cytokines, which play an incompletely understood
role in pituitary physiology. Cases of sarcoidosis have been
already reported in the setting of known granulomatous
inﬂammation of the target organs [67]. Whether the pres-
ence of a pituitary adenoma can stimulate local inﬂam-
mation disorders predisposing to sarcoid formation is an
Pituitary (2010) 13:8–17 15
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hypothesis is correct it could explain the evidence of sar-
coidosis within a pituitary adenoma.
Conclusion
‘‘Combined sellar pathology’’ in case of patients operated
upon for a pituitary adenoma is extremely rare. However, a
great variety of lesions can coexist with pituitary adenomas
and referred to as ‘‘collision sellar lesions’’. Histological
studies are essential to conﬁrm the diagnosis. Still no
proven pathogenetic mechanism has explained the rela-
tionship between a pituitary adenoma and a second sellar
lesion. However, interesting theories have been suggested.
Progress in molecular genetics, new technologies and fur-
ther research will shed more light on the mechanisms of
pituitary adenomatogenesis/tumorigenesis and their poten-
tial interaction.
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